No one can predict the result of NVAX's phase 3 trial. However, I don't count out any potential winners in the vaccine race even though now it seems very likely that NVAX won't be the first one to distribute vaccines at massive scale.
That being said, as long as the result of phase 3 trial isn't a complete failure, I think the crowd frenzy will keep pushing NVAX's price up.
To be on the safe side, I would market buy 33% of my overall position and limit buy the remaining in the demand zone.